A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

In second- or later-line setting, combination cut risk of disease progression or death by ...

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3Data highlight the potential of this ...

As of Wednesday, February 25, CytomX Therapeutics, Inc.’s CTMX share price has surged by 7.44%, which has investors questioning if this is right time to sell.

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...

过去两年，细胞治疗赛道正经历一场隐秘而猛烈的底层重构。礼来收购Orna、艾伯维拿下Capstan、BMS也躬身入局……跨国巨头们超60亿美元的密集扫货，释放出一个极其明确的信号：In vivo CAR-T已处于产业化爆发的前夕。 传统Ex vivo CAR-T动辄数十万美元的定价与繁杂的制备周期，使其深陷个性化定制的商业泥沼，而In vivo CAR-T正以颠覆者的姿态，将细胞疗法拉回现代制药的规 ...

As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.